The agency is changing the standard of evidence required for Covid-19 vaccine approval in the US, Dr. Vinay Prasad, the new director of the FDA’s Center for Biologics Evaluation and Research, and FDA Commissioner Dr. Marty Makary, said in an editorial published Tuesday in the New England Journal of Medicine

The change marks a shift in the Food and Drug Administration’s policy on approving COVID-19 vaccines, which the new commissioner described as a “one-size-fits-all regulatory framework.”

The FDA announced it will limit access to Covid-19 vaccines going forward to people 65 and older and others at high risk of serious illness